NCT03814772

Brief Summary

Based on the principle of patient blood management, this study aims to reduce the risk of blood transfusion in allogeneic liver transplantation patients, to ensure the safety of blood transfusion, and to provide new methods and basis for restrictive blood transfusion.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 20, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 24, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

March 20, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

February 21, 2019

Status Verified

February 1, 2019

Enrollment Period

9 months

First QC Date

January 20, 2019

Last Update Submit

February 20, 2019

Conditions

Blood Transfusion Complication

Keywords

liver transplantationblood transfusionPatient blood management

Outcome Measures

Primary Outcomes (1)

  • one year mortality

    All-cause mortality

    2019-2021

Secondary Outcomes (1)

  • Intraoperative blood transfusion

    2019-2021

Study Arms (1)

Liver transplant

1. 18 years to 65 2. 48h preoperative biochemical indicators, blood general indicators, coagulation test complete

Procedure: Liver transplant

Interventions

Liver transplantPROCEDURE

blood transfusion

Liver transplant

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Allogeneic liver transplantation surgery

You may qualify if:

  • h preoperative biochemical indicators, blood general indicators, coagulation test complete

You may not qualify if:

  • \. Inspection information is not detailed 2. Blood transfusion information is not detailed 3.Postoperative medical record information is not detailed

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

the Third Xiangya Hospital of Central South University

Changsha, Hunan, 410006, China

RECRUITING

MeSH Terms

Conditions

Transfusion Reaction

Interventions

Liver Transplantation

Condition Hierarchy (Ancestors)

Hematologic DiseasesHemic and Lymphatic DiseasesImmune System Diseases

Intervention Hierarchy (Ancestors)

Tissue TransplantationCell- and Tissue-Based TherapyBiological TherapyTherapeuticsDigestive System Surgical ProceduresSurgical Procedures, OperativeOrgan TransplantationTransplantation

Central Study Contacts

Rong Gui, doctor

CONTACT

+8615200828442aguirong@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Target Duration
2 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 20, 2019

First Posted

January 24, 2019

Study Start

March 20, 2019

Primary Completion

December 1, 2019

Study Completion

December 31, 2021

Last Updated

February 21, 2019

Record last verified: 2019-02

Locations

CN(1)